Bristol Myers Squibb Says FDA Accepts For Priority Review Its Application For Repotrectinib For Treatment Of Patients With Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Bristol Myers Squibb's New Drug Application for repotrectinib, a treatment for ROS1-positive non-small cell lung cancer, granting it Priority Review with a PDUFA goal date of November 27, 2023.
May 30, 2023 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's repotrectinib receives FDA Priority Review for treating ROS1-positive non-small cell lung cancer, with a PDUFA goal date of November 27, 2023.
The FDA's acceptance of Bristol Myers Squibb's NDA for repotrectinib and granting it Priority Review is a positive development for the company. This indicates that the FDA recognizes the potential benefits of the drug and is committed to expediting its review process. If approved, repotrectinib could become a significant revenue driver for Bristol Myers Squibb, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100